Regenerative medicine: Translation of current research into clinical products is one of the topics at SMi's Stem Cells 2011 conference
The current technological and regulatory barriers to the development of this exiting branch of modern medicine, and how to overcome and surpass them will be discussed by by leading academics working in regenerative medicine and cell biology
LONDON, ENGLAND, January 14, 2011
Recently legislation has been passed in the US which advocates stem cell research. Also, very recently the first stem cell therapy was put into clinical trials. This finally makes the development of stem cell treatments a realistic prospect for pharma companies.SMi is pleased to announce its 3rd annual Stem Cells 2011 conference that will explore the latest scientific advances and business opportunities offered by stem cell research. There will be a variety of presentations from leading academics working in regenerative medicine and cell biology as well as industry professionals specialising in the transferral of stem cell research from preclinical to clinical development.
Hear keynote addresses from Professor Dame Julia Margaret Polak, Head of the Tissue Engineering and Regenerative Medicine Centre, Imperial College London and John McDonald, Cellular Analysis Technical Specialist, Roche Diagnostics.
Don't miss your chance to network with the leaders in this field, and look towards the future of this rapidly expanding area of medicine, these include:
• Michaela Sharpe, Drug Safety R&D Regenerative Medicine Expert, Pfizer
• Julia Polak, Founder and Former Head of The Tissue Engineering and Regenerative Medicine Centre, Imperial College London
• John McDonald, Cellular Analysis Technical Specialist, Roche Diagnostics
• Sara Rankin, Reader in Leukocyte and Stem Cell Biology, National Heart & Lung Institute, UK
• Dominique Bonnet, Head of Haematopoietic Stem Cell Laboratory, Cancer Research UK
• Paul Martin, Deputy Director of the Institute for Science and Society, University of Nottingham
• Marc Lalande, Director, University of Connecticut Stem Cell Institute
The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi's highly targeted conferences, workshops and publications. For more information visit http://www.smi-online.co.uk